Mutations in Candida glabrata FKS genes, which encode the echinocandin target enzyme, are independent risk factors for treatment failures during invasive candidiasis. We retrospectively compared the ability of caspofungin susceptibility testing methods to identify C. glabrata FKS mutant isolates and predict outcomes among patients at our center. Eight percent (10/120) of sterile-site C. glabrata isolates harbored FKS1 (n ‫؍‬ 3) or FKS2 (n ‫؍‬ 7) mutations, including 32% (10/32) recovered from patients with prior echinocandin exposure. Median echinocandin exposures for mutant and nonmutant isolates were 55 (range, 7 to 188) and 13 (3 to 84) days, respectively (P ‫؍‬ 0.004). Sensitivity and specificity of the CLSI caspofungin resistance breakpoint MIC (>0.12 g/ml by broth microdilution using RPMI medium [BMD-RPMI]) were 90% (9/10) and 3% (3/110), respectively, for identifying FKS mutants. Sensitivity and specificity of receiver-operator characteristic (ROC) curve-derived breakpoints by BMD-RPMI, BMD-antibiotic medium 3, Etest, and YeastOne ranged from 70 to 100% and 89 to 95%, respectively; susceptibility rates varied from 83 to 90%. The 14-day echinocandin treatment success rate was 67% (44/66); failure was more likely with prior echinocandin exposure (P ‫؍‬ 0.002) or infection with an FKS mutant (P ‫؍‬ 0.0001) or echinocandin-resistant isolates by BMD-AM3, Etest, and YeastOne (P < 0.03). The failure rate among patients with prior exposure and infection with a resistant isolate was 91% (10/11); it was 22% (12/55) among others (P < 0.0001).
C
andida glabrata is the second most common cause of invasive candidiasis in the United States (1) . The echinocandin class of antifungals, including caspofungin, has become the preferred therapy for invasive candidiasis due to C. glabrata and other species demonstrating decreased azole susceptibility (2) . Echinocandin resistance has been uncommon, but reports suggest that the incidence is increasing, particularly among C. glabrata isolates (1, 3, 4) . Resistance is mediated by point mutations in hot spots of FKS genes, which encode the target enzyme ␤-1,3-D-glucan synthase. Recently, the Clinical and Laboratory Standards Institute (CLSI) proposed species-specific echinocandin MIC breakpoints to differentiate FKS mutant strains from wild-type (WT) Candida (5) . The revised breakpoints were based on the reference broth microdilution method (BMD) and are sensitive for classifying FKS mutant strains as resistant. To date, however, data on correlations between echinocandin MICs and outcomes among patients with invasive candidiasis who are treated with these drugs are conflicting (6) (7) (8) , and the clinical role of in vitro echinocandin susceptibility testing is unclear.
In fact, as a result of optimizing the sensitivity of MICs for detecting FKS mutations, the specificity of caspofungin breakpoints may be too low to be useful clinically. These concerns are most relevant for C. glabrata isolates, as caspofungin resistance rates based on the proposed breakpoint (Ͼ0.12 g/ml) are highly variable and approach 100% at some centers (4, 6) . Factors that may impact MICs include variations between drug lots (9, 10) , choice of dissolving solvent (11) , and evaluator bias (12) . It has been proposed that results can be improved with the use of dimethyl sulfoxide (DMSO) rather than sterile water to dissolve caspofungin (11) , as well as using optical density (OD) rather than visual endpoints (13) . Given the concerns about the BMD method, many clinical microbiology laboratories now use commercially available methods, such as Etest or Sensititre YeastOne panels, for routine susceptibility testing. These methods are less labor-intensive and have shown good essential agreement with BMD for wild-type C. glabrata (14) (15) (16) (17) . However, rates of agreement for FKS mutant strains are unknown, and resistance breakpoints have not been established.
We recently demonstrated that the detection of an FKS mutation was an independent risk factor for failure of echinocandin therapy among patients at our center with invasive candidiasis due to C. glabrata (4) . The results suggest that genotypic resistance testing of isolates is useful in guiding therapy, but molecular assays are not standardized or practical for most clinical microbiology laboratories. Of note, a BMD caspofungin MIC of Ͼ0.5 g/ml (rather than Ͼ0.12 g/ml) was associated with both the presence of FKS mutations and treatment failure by univariate analysis (4) . Therefore, although the caspofungin MIC was not independently predictive of treatment failure, the data suggest it is useful clinically as a proxy for FKS mutations. The objectives of this study were to compare a variety of testing methods to the BMD reference method for the identification of C. glabrata FKS mutant isolates and to determine if MICs correlate with treatment outcomes. In determining correlations with outcomes, we assessed the performance of caspofungin MICs and FKS mutations in the presence and absence of prior echinocandin exposure.
MATERIALS AND METHODS

Isolates.
One hundred twenty C. glabrata isolates were selected from the biorepository at the University of Pittsburgh Mycology Research Unit. Isolates were collected from sterile sites of patients with invasive candidiasis from 2007 to 2011; 39 isolates were included in our earlier study (4) . Prior to testing, isolates were retrieved from Ϫ80°C stock, subcultured onto Sabouraud dextrose agar plates, grown at 35°C for 24 to 48 h, and subcultured again for 24 h.
Echinocandin susceptibility testing. Caspofungin MICs were determined in triplicate according to CLSI document M27-A3 (18), using a 50% turbidity endpoint at 24 h in RPMI 1640 (buffered to pH 7.0 with morpholinepropanesulfonic acid) or antibiotic medium 3 (BMD-RPMI and BMD-AM3, respectively). Endpoints were determined independently by two investigators, and discrepancies were resolved by a third. All MICs were within one 2-fold dilution upon repeat testing, and modal MICs were analyzed. We used caspofungin because it is the formulary echinocandin at our center, and 95% (63/66) of patients treated with an echinocandin received this agent. Standard caspofungin powder was obtained from the manufacturer (lot number 0000086468; Merck, Rahway, NJ). We dissolved pure powder in both sterile water and dimethyl sulfoxide (DMSO), which is reported to reduce lot-to-lot variability (11) . In addition to a visual turbidity endpoint, we determined MICs in parallel by a Ն50% reduction in optical density as recommended by the European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) (13) . The range of concentrations tested was 0.015 to 16 g/ml. We next determined caspofungin MICs by Etest (BioMérieux) and Sensititre YeastOne (Trek Diagnostics) according to the manufacturers' instructions. Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were used as quality controls. The quality-control strains were incorporated into each set of experiments, and MICs were within the expected range (19) .
Determination of FKS mutations. C. glabrata genomic DNA was extracted from yeast cells grown overnight in YPD broth (2% yeast extract, 4% peptone, 4% dextrose) and purified using a Wizard genomic DNA purification kit (Promega, Madison, WI). Hot spots 1 and 2 of FKS1 and FKS2 were amplified using PCR as previously described (4, 20) . Standard Sanger DNA sequencing of purified PCR amplicons was performed with a 3130 DNA analyzer (Applied Biosystems, Carlsbad, CA). DNA sequences were analyzed with a Sequence Scanner (Applied Biosystems), and the corresponding amino acid sequences were compared to sequences in C. glabrata databases (http://www.ncbi.nlm.nih.gov/blast/).
Patient outcomes. To be considered for inclusion in the evaluation of clinical outcomes, patients with invasive candidiasis due to C. glabrata must have been treated with an echinocandin for Ն3 days following the diagnosis or developed a breakthrough infection while receiving an echinocandin for Ն3 days as preventive or empirical therapy. In cases of candidemia, vascular catheters had to be removed within 48 h of starting an echinocandin. In cases of intra-abdominal abscesses, drainage had to be performed. Exclusion criteria included treatment with an antifungal other than an echinocandin, death prior to receiving 3 days of antifungal therapy, and retention of a vascular catheter or lack of drainage for Ͼ48 h after the start of antifungal therapy (4). In addition, three patients from a long-term care unit within our center were excluded due to incomplete medical records. Prior echinocandin exposure was defined as the receipt of an echinocandin at any time in the past; data were expressed as the cumulative number of days patients received echinocandin therapy prior to invasive candidiasis. Treatment failure was assessed at day 14 and defined using consensus definitions of outcomes for antifungal therapy (21) or as a breakthrough infection. Outcomes were assigned retrospectively. The study was approved by the University of Pittsburgh Institutional Review Board.
Data analysis. Statistical analyses were performed using the PASW Statistics 18 software program (SPSS Inc., Chicago, IL). Differences in MICs were compared using Wilcoxon rank-sum and the overlap of 2-fold dilutions as described previously (10) . For Etest, MIC values were rounded to the next 2-fold dilution. Essential agreement between tests was determined by comparing each method to the reference BMD method in RPMI and was defined by MICs within one dilution (Յ2-fold difference). Using the revised CLSI breakpoints for caspofungin, we defined resistance as a MIC of Ͼ0.12 g/ml in our primary analysis (intermediate isolates were classified as resistant). In separate analyses, resistance was defined as Ͼ0.25 g/ml (intermediate isolates were classified as susceptible) (5).
Optimal cutoff values for each testing method were determined by receiver-operator characteristic (ROC) curve analysis. Sensitivity and specificity of cutoff values were compared using the McNemar's chi-squared test (22) . Rates of treatment failure and success were compared by chi-squared or Fisher's exact test. Significance was defined as P Յ 0.05 (two tailed).
RESULTS
Caspofungin MICs.
Caspofungin MICs against C. glabrata isolates according to each method are listed in Table 1 . MICs by BMD did not significantly differ with the use of DMSO or optical density endpoints (R 2 ϭ 0.78 and 0.81, respectively) ( Fig. 1A and B). Among alternative methods, essential agreement with BMD-RPMI was highest for Etest and YeastOne (96 and 90%, respectively) and significantly lower for BMD-AM3 (14%; P Ͻ 0.001).
Caspofungin MICs and FKS mutations. Eight percent (10/ 120) of isolates harbored FKS1 (n ϭ 3) or FKS2 (n ϭ 7) gene mutations ( Table 2 ). All mutant isolates were recovered from patients previously exposed to an echinocandin (compared to 19% [21/110] of wild-type isolates; P Ͻ 0.0001). The rate of FKS mutations among isolates recovered from patients with prior echinocandin exposure was 32% (10/31). The duration of prior echinocandin exposure was greater for the FKS mutant (median, 55 days; range, 7 to 188 days) than for the wild-type isolates (median, 13 days; range, 3 to 84 days; P ϭ 0.004). In keeping with these findings, median caspofungin MICs were higher among isolates previously exposed to echinocandins (data not shown; P Ͻ 0.0001 for each testing method) and those with FKS mutations (P Ͻ 0.0001 for each testing method) ( Table 1) . The current CLSI breakpoint MIC by standard BMD-RPMI was 90% (9/10) sensitive for identifying FKS mutant isolates, but specificity was only 3% (3/110). Using a more conservative resistance breakpoint of Ͼ0.25 g/ml (intermediate isolates were classified as susceptible), sensitivity and specificity were 80% (8/10) and 18% (20/110), respectively. ROC curve analysis identified optimal breakpoint MICs for the identification of FKS mutant isolates by each testing method (Table 3) . Based on these cutoffs, rates of caspofungin susceptibility varied between 83 and 90%. ROC-derived breakpoints were more specific than CLSI breakpoints for BMD-RPMI (P Ͻ 0.0001), YeastOne (P Ͻ 0.0001), and Etest (P Ͻ 0.0001). In fact, an Etest resistance breakpoint of Ͼ0.25 g/ml provided the highest likelihood ratio (15.7), with 100% (10/10) sensitivity and 94% (103/110) specificity for identifying FKS mutant isolates.
Caspofungin MICs and clinical outcomes. Sixty-six patients with invasive candidiasis were treated with an echinocandin (63 caspofungin, 1 anidulafungin, and 2 micafungin treatments), including all patients infected with FKS mutant C. glabrata. The 14-day treatment success and failure rates were 67% (44/66) and 33% (22/66), respectively. The sensitivity and specificity of each ROC-derived breakpoint are listed in Table 4 . Etest and BMD-RPMI were the susceptibility testing methods that generated MICs with the highest and lowest sensitivities for identifying treatment failure (50% [11/22] versus 32% [7/22] ; P ϭ 0.13). Patients who failed echinocandin therapy were significantly more likely to have prior echinocandin exposure, infection with a C. glabrata FKS mutant isolate, or infection with an isolate exhibiting a MIC above the ROC-derived cutoff value by BMD-AM3, YeastOne, or Etest (Table 5 ). Prior echinocandin exposure and caspofungin MICs of Ͼ0.25 g/ml by Etest were the most sensitive predictor variables for treatment failure (59% [13/22] and 50% [11/22] , respectively). Positive and negative predictive values of the variables for identifying treatment failures ranged from 54 to 90% and 75 to 80%, respectively (Table 5) .
A breakdown of treatment failures based on prior echinocandin exposure and caspofungin MIC (as determined by Etest) is presented in Fig. 2 . The treatment failure rate among patients who were not previously exposed to an echinocandin was 20% (9/45); the rate among patients who were previously exposed was 59% (13/22) (P ϭ 0.002). In the latter group, the failure rate among patients who were infected with C. glabrata isolates for which caspofungin MICs were Ͼ0.25 g/ml was 91% (10/11), compared to 22% (12/55) for all other patients (P Ͻ 0.0001). Of note, the failure rate for patients infected with FKS mutant C. glabrata was 90% (9/10).
DISCUSSION
With recent reports that echinocandin antifungals have become the agents of choice against invasive candidiasis due to C. glabrata (23, 24) , there is a heightened need for strategies to identify isolates that are unlikely to respond to echinocandin therapy. We previously demonstrated that C. glabrata FKS mutations were independently associated with echinocandin treatment failures (4); however, standardized molecular assays are not currently developed for use in clinical microbiology laboratories. In this study, we have shown that ROC-derived caspofungin MIC breakpoints were sensitive and specific for the identification of C. glabrata isolates carrying FKS mutations and had good positive and negative predictive values for failure of echinocandin therapy (Table 5) . Most importantly, a paradigm that considers prior echinocandin exposure and caspofungin MICs accurately classified treatment outcomes among patients with C. glabrata invasive candidiasis (Fig. 2) . In fact, patients who were previously exposed to an echinocandin and infected with an isolate that was resistant by our Etest breakpoint were as likely to fail echinocandin therapy as patients infected with an FKS mutant isolate (91% [10/11] versus 90% [9/10], respectively). The results suggest that our paradigm is a useful proxy for the detection of FKS mutations, and caspofungin MICs might be incorporated into management strategies against C. glabrata invasive candidiasis.
The contrasts among patients with and without prior echinocandin exposure were stark. In the absence of prior exposure, the treatment failure rate was low (20% [9/45]), FKS mutations were not detected, caspofungin MICs by each testing method were lower, and caspofungin resistance (as defined by ROC-derived breakpoints) was rare (7% [3/45] by Etest). However, in the face of prior exposure, the treatment failure and FKS mutation rates were 59% (13/21) and 32% (10/31), respectively (P ϭ 0.002 and P Ͻ 0.0001, respectively), caspofungin MICs were significantly higher (P Ͻ 0.0001 by each method), and caspofungin resistance was more common (52% [11/21] by Etest; P Ͻ 0.0001). The outcomes among patients who had not previously received an echinocandin were in keeping with echinocandin clinical trial data for C. glabrata invasive candidiasis (23) . Our paradigm suggests that sus- ceptibility testing in this setting is best utilized for patients in whom the initial clinical or microbiologic responses to caspofungin are unsatisfactory. It is important to understand, however, that most caspofungin treatment failures in these patients are likely to reflect clinical rather than microbiologic resistance, as only 11% (1/9) of patients were infected with isolates that exhibited MICs above the Etest breakpoint and none were infected with an FKS mutant. Conversely, microbiologic resistance does not preclude the possibility that an echinocandin will be effective, as 67% (2/3) of patients infected with putatively resistant isolates were treated successfully. The data highlight that microbiologic resistance is not the sole determinant of responses to antifungal therapy, since factors like host immune function, underlying diseases, severity of illness, intravenous catheter removal, adjunctive surgical interventions, and pharmacokinetic/pharmacodynamic parameters also play crucial roles (25) . Our paradigm is less clear-cut for patients with prior echinocandin exposure. In general, the best approach is likely to avoid caspofungin or other echinocandins as initial therapy in patients with more than a few days of prior exposure. The shortest duration of echinocandin use associated with an FKS mutation was 7 days. If patients are treated initially with a non-echinocandin regimen, the results of susceptibility testing may be useful for subsequent decision-making. Our data suggest that a large percentage of patients will not be infected with caspofungin-resistant or FKS mutant isolates, particularly if they have only received short courses of echinocandin therapy previously. Given the apparent superiority of echinocandins to other agents for treating C. glabrata invasive candidiasis (23, 24) , it would be reasonable to consider switching to an echinocandin for at least some of the patients infected with nonresistant isolates. In this regard, a low caspofungin MIC may be useful for patients who have not responded to their initial regimen. Similarly, the detection of resistance among patients previously exposed to an echinocandin would be valuable for eliminating these agents as treatment options. Unfortunately, the duration of prior echinocandin exposure was not helpful in identifying resistant isolates. Although previous echinocandin courses were significantly longer in patients infected with FKS mutants than nonmutant isolates, the overlap between the groups did not allow the identification of an accurate exposure breakpoint.
Ultimately, the utility of echinocandin MICs as a management tool will depend upon the reproducibility of results across institutions (12) . Unfortunately, caspofungin MIC distributions in studies using the standard BMD-RPMI method are variable, and currently recommended control strains are insensitive at detecting this variability (15) . Our MICs were higher than those reported by a large reference laboratory (5, 26) but were consistent with findings from other groups (4, 6, 27) . Adaptations to the BMD protocol, such as dissolving caspofungin in DMSO (11) or reading endpoints by optical density (13) , have been proposed to reduce lot-to-lot variations and evaluator bias, respectively, but they did not change the MIC distribution in our experience (essential agreement of 93 and 98%, respectively). The revised CLSI caspofungin MIC breakpoint for C. glabrata (Ͼ0.12 g/ml) aims to be sensitive for detecting emerging resistance associated with FKS mutations and predictive of treatment failure. However, it was not useful in either regard at our center. Ninety percent (9/10) of FKS mutants were defined as resistant, but so were 97% (107/110) of nonmutant isolates. Results were not significantly different using a resistance cutoff of Ͼ0.25 g/ml (80% [8/10] and 82% [90/110], respectively). Not surprisingly then, the sensitivity of resistant MICs for predicting echinocandin treatment failure was 95% (21/ 22), but the specificity was 0% (0/44). It is unclear if the poor performance of the CLSI breakpoint is unique to our center and its distribution of caspofungin MICs, or if the breakpoint will require further adjustments as more data are compiled. Of note, a recent pharmacodynamic evaluation of caspofungin against C. glabrata FKS mutant and wild-type strains in a neutropenic mouse model of hematogenously disseminated infection also supported a higher breakpoint MIC. In the mouse study, caspofungin MICs of Ͼ1 g/ml were associated with reduced treatment efficacy and failure to achieve pharmacodynamics targets (28) . It is possible that other methods of caspofungin susceptibility testing perform better than BMD-RPMI in identifying resistant isolates. BMD-AM3 has been reported to be superior for distinguishing C. albicans, C. krusei, and C. tropicalis FKS mutants (29) , but the method has not been evaluated for C. glabrata. In keeping with previous reports (12, 29) , caspofungin MICs against our isolates were lower in AM3 than in RPMI. An optimal breakpoint of Ͼ0.06 g/ml, as determined by ROC analysis, demonstrated sensitivity and specificity of 70 and 95%, respectively, for the detection of FKS mutants, which was virtually identical to the ROCderived BMP-RPMI breakpoint (70 and 93%, respectively). BMD-AM3 performed slightly better than BMD-RPMI in identifying treatment failures (sensitivity, 36 versus 32%; specificity, 95 versus 86%; likelihood ratio, 8.0 versus 2.3), but differences did not achieve statistical significance.
Likewise, the commercially available Etest and YeastOne assays showed trends toward better performance than BMD-RPMI. Caspofungin breakpoints by these methods have not been proposed, but CLSI breakpoints are well known to misclassify Candida species if applied to Etest MICs (30) . ROC analysis identified Ͼ0.25 g/ml as the optimal cutoff for detecting FKS mutations and predicting treatment failures by both methods. Etest performed particularly well, with a sensitivity, specificity, and likelihood ratio for identifying FKS mutations of 100% (10/10), 94% (103/110), and 15.7, respectively. The sensitivity, specificity, and likelihood ratio of the Etest breakpoint in predicting treatment failures were 50% (11/22), 93% (41/44), and 7.3, respectively, and positive and negative predictive values were 79% each (11/14 and 41/52, respectively). It is notable that the performance of the Etest breakpoint, in the absence of prior echinocandin exposure, was in keeping with the 90/60 rule, which was originally used to describe the performance of the fluconazole breakpoint MIC in predicting treatment responses among patients with mucosal and systemic candidiasis (25) . The 90/60 rule proposes that an interpretive breakpoint is appropriate if 90% of susceptible isolates respond to treatment compared to 60% of resistant isolates. In previous studies of Candida isolates with wild-type FKS, Etest showed excellent agreement with BMD-RPMI (14, 31, 32) . Our findings are consistent with data for other Candida spp., for which Etest caspofungin MICs discriminated perfectly between FKS mutant and wild-type strains (33) . The cumulative experience suggests that commercially available susceptibility testing assays are convenient, reproducible alternatives to BMD methods, which may provide clinicians with useful microbiologic information.
At present, data describing the relationship between echinocandin MICs and responses to therapy are conflicting. Our finding of a correlation between caspofungin MICs and treatment outcomes is consistent with a recent study of C. glabrata bloodstream isolates collected between 2001 and 2010 at a large center (8) and an earlier study of 17 Candida isolates recovered from patients with breakthrough invasive candidiasis while receiving micafungin (34) . In the former study, 13 patients received echinocandin monotherapy with caspofungin or micafungin for C. glabrata bloodstream infections due to a strain that was resistant according to the CLSI breakpoints. Treatment was successful in only 38.5% (5/13) of these patients, compared to Ͼ90% of patients infected with susceptible isolates. In the latter study, FKS mutations and caspofungin MICs of Ͼ2 g/ml were demonstrated for 5 C. glabrata and 2 C. tropicalis isolates. As in our experience, resistance was encountered in the presence of extensive prior echinocandin exposure (median, 33 days). In contrast to these two reports, there was no correlation between elevated MICs and failed therapy in a study of Candida isolates recovered from patients with esophageal and invasive candidiasis (6) . In fact, outcomes were better among patients infected with isolates exhibiting caspofungin MICs of Ͼ2 g/ml compared to those with MICs of Ͻ1 g/ml. The interpretation of C. glabrata data in this study was limited by the fact that only 15 isolates were available from patients treated with caspofungin, and MICs were clustered at 0.5 or 1 g/ml. In addition, isolates were almost exclusively recovered from patients before treatment with caspofungin. Therefore, the study does not contradict our conclusion that caspofungin susceptibility testing is likely to be most relevant in the setting of prior echinocandin exposure.
In conclusion, future studies are needed to validate our findings and clarify the roles of echinocandin susceptibility testing in clinical practice. Moreover, thorough investigations of other echinocandins and Candida spp. are warranted. Our data suggest that susceptibility testing holds promise as a tool to guide antifungal therapy, particularly among patients previously exposed to the echinocandins. Nevertheless, the field faces challenges, including the establishment of testing methods that reduce variability. At the same time, studies are needed to define the roles of FKS genotyping in guiding treatment and to identify additional molecular mechanisms that may diminish echinocandin efficacy. Despite the present uncertainties about the clinical role of echinocandin susceptibility testing, it is important for centers to conduct ongoing epidemiologic surveillance with one of the methods described in this study to identify changes in institutional ecology and resistance patterns.
